Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SyNic (nicotine)
- Development stage
- Preclinical
- Lead developer
- Zanoprima Life Sciences
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
SyNic is a high-purity synthetic nicotine product line developed by Zanoprima Life Sciences, produced through a patented non-tobacco-based process. The product line includes a transdermal patch (SyNic Transdermal Nicotine Patch) and oral nicotine products (white snus). The transdermal formulation is being developed for the treatment of neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and age-related cognitive decline, based on the neuroprotective properties of nicotine. As a nicotinic acetylcholine receptor agonist, it aims to modulate cholinergic signaling. The synthetic production method ensures the absence of tobacco-specific nitrosamines (TSNAs) and other impurities associated with tobacco-derived nicotine, potentially offering a safer profile for long-term therapeutic use.
- Brand names
- SyNic
- Other names
- SyNic patchSyNic Transdermal Nicotine PatchSyNic Oral Productstransdermal nicotine patchsynthetic nicotine
02
Targets
α3β4 nAChR (α3β4 nicotinic receptor)Muscle-type nicotinic acetylcholine receptorα4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on SyNic (nicotine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SyNic (nicotine).